Abstract Background: Iron overload is a clinical consequence of repeated blood transfusions and causes significant organ damage, morbidity, and mortality in the absence of proper treatment. The primary targets of Iron chelators used for treating transfusional Iron overload are the prevention of Iron ingress into tissues and its intracellular scavenging. The present study was aimed at elucid...

abstract background: iron overload is a clinical consequence of repeated blood transfusions and causes significant organ damage, morbidity, and mortality in the absence of proper treatment. the primary targets of iron chelators used for treating transfusional iron overload are the prevention of iron ingress into tissues and its intracellular scavenging. the present study was aimed at elucidatin...

PURPOSE The iron chelating agent deferoxamine mesylate USP (Desferal, Ciba, Summit, NJ) is commonly used in the treatment of acute iron intoxication and chronic iron overload (associated with the transfusion-dependent anemias). When used for prolonged periods of time or in high doses deferoxamine is attended by a range of ocular toxicities. The visual symptoms associated with deferoxamine admin...

Background: Iron is an essential mineral for normal cellular physiology but its ‎overload can lead to cell injury. For many years, deferoxamine injection has been used ‎as an iron chelator for treatment of iron overload. The aim of this study is to compare ‎oral deferoxamine, activated charcoal, and vitamin C, as an absorbent factor of Fe, in ‎changing the serum level of iron in iron overload r...

BACKGROUND AND PURPOSE Iron catalyzes the formation of damaging reactive species during cerebral reperfusion. Brain iron concentration is highest at birth, so the brain of the asphyxiated newborn may be at increased risk of iron-dependent injury. We investigated whether the ferric iron chelator deferoxamine could reduce hypoxic-ischemic brain injury in neonatal rats. Because deferoxamine has co...

background: iron is an essential mineral for normal cellular physiology but its ‎overload can lead to cell injury. for many years, deferoxamine injection has been used ‎as an iron chelator for treatment of iron overload. the aim of this study is to compare ‎oral deferoxamine, activated charcoal, and vitamin c, as an absorbent factor of fe, in ‎changing the serum level of iron in iron overload r...

Desferal, deferoxamine mesylate USP, is an iron-chelating agent, available in vials for intramuscular, subcutaneous, and intravenous administration. Desferal is supplied as vials containing 500 mg and 2 g of deferoxamine mesylate USP in sterile, lyophilized form. Deferoxamine mesylate is N-[5-[3-[(5­ aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N­ hydroxyacetamido)pentyl]carbamoyl]p...

Vibrio vulnificus can use the standard iron chelator deferoxamine (Desferal) for efficient iron-uptake via the specific receptor DesA, which is encoded by desA. We investigated the ubiquity of the deferoxamine-mediated iron-uptake system in V. vulnificus strains and the potential risk of the system. By polymerase chain reaction (PCR), desA was found in 10 of 10 clinical strains and in 9 of 10 e...

Enterovirus 71 is one of the major causative agents of hand, foot and mouth disease in children under six years of age. No vaccine or antiviral therapy is currently available. In this work, we found that the number of B cells was reduced in enterovirus 71-infected mice. Deferoxamine, a marine microbial natural product, compensated for the decreased levels of B cells caused by enterovirus 71 inf...